Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

24 May 2017, Bangkok – This April and May, the targeted malaria elimination (TME) study in Laos’ final prevalence survey evaluated new tools to detect asymptomatic malaria. These included new rapid diagnostic tests (RDTs) that may be similar in sensitivity to a PCR performed on dried blood spots and reading machines that fire a laser at RDTs and use a thermal camera to detect faint positive results that would be beyond the range of the human eye.

Various researchers

Developed by Intellectual Ventures Laboratory with support from the Bill and Melinda Gates Foundation via Global Good, both are potential new malaria elimination tools as they could identify rapidly the asymptomatic reservoir of falciparum infections. Results are expected late summer 2017 comparing the new RDTs and readers to a gold standard method of malaria detection, the quantitative PCR results from Mallika Imwong’s molecular laboratory at MORU.

A team led by LOMWRU scientists Mayfong Mayxay and Koukeo Phommasone (bottom right), Tiengkham Pongvongsa (bottom centre), head of malaria control in Savannakhet Province, and WWARN’s Mehul Dhorda and MORU’s Lorenz von Seidlein and Tom Peto hosted Kevin Nichols and Stephen Burkhor (top left) of Intellectual Ventures Laboratory (IVL) to field test the tools.

Funded by the Bill and Melinda Gates Foundation, the MORU TME project seeks to accelerate malaria elimination by providing mass drug administrations (MDA) to communities that have relatively high P. falciparum prevalence, access to village health malaria workers and where every household has one or more long lasting insecticide treated bed nets. The TME project operates in four Greater Mekong Subregion countries: Myanmar, Cambodia, Laos and Viet Nam.

In Laos, the TME project focuses on rural villages in Savannakhet province, which has the third highest malaria incidence in Lao PDR. A survey conducted in 18 rural villages in Savannakhet in 2015 using uPCR detected Plasmodium infections in 175 of 888 samples (20%). Most villages in Savannakhet are relatively accessible and malaria elimination has a high priority for the local government. LOMWRU’s Dr Mayfong Mayxay is the principal investigator (PI) for the Lao PDR study, while Dr Koukeo Phommasone is the field site PI.

Similar stories

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.